[시장보고서]세계의 섬유근육통 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

세계의 섬유근육통 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Fibromyalgia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

상품코드 : 1550125

리서치사 : Persistence Market Research

발행일 : 2024년 09월

페이지 정보 : 영문 231 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,216,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,539,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,273,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

Persistence Market Research는 세계의 섬유근육통 치료 시장에 대한 광범위한 보고서를 발표했습니다. 이 보고서는 시장 성장 촉진요인, 동향, 기회, 과제 등 주요 시장 역학을 종합적으로 분석하여 시장 구조에 대한 깊은 인사이트를 제공합니다.

주요 인사이트

섬유근육통 치료 시장 규모(2024E) : 15억 달러
예측 시장 규모(2033F) : 27억 달러
세계 시장 성장률(CAGR 2024-2033년) : 6.7%

섬유근육통 치료 시장 : 조사 범위

섬유근육통 치료 시장은 광범위한 근골격통, 피로, 인지 장애를 특징으로 하는 만성 질환을 관리하는 데 사용되는 광범위한 치료 접근법을 포함합니다. 섬유근육통은 세계 수백만 명이 앓고 있으며, 그 관리에는 종종 약물요법, 물리치료, 생활습관의 개선이 필요합니다. 이 시장은 병원, 전문 클리닉, 재활센터 등 여러 부문에 서비스를 제공합니다. 성장의 원동력은 섬유근육통에 대한 인식 증가, 치료법의 진보, 다양한 의료 현장에서의 증상 관리를 위한 집학적 접근의 이용 확대입니다.

시장 성장 촉진요인 :

세계의 섬유근육통 치료 시장을 견인하는 몇 가지 주요 요인이 있습니다. 섬유근육통의 이환율이 세계적으로 상승하고 있기 때문에 이 증상에 대한 효과적인 치료를 요구하는 환자가 늘어나 시장의 성장을 뒷받침하고 있습니다. 새로운 의약품 제형, 비 약물 치료 및 원격 의료 애플리케이션과 같은 치료 옵션의 기술적 진보는 섬유 근육 통증 관리의 효능과 접근성을 향상시키고 시장 확대를 더욱 강화하고 있습니다. 또한 조기 진단의 중요성과 개인화 치료 계획 수립에 대한 의식이 높아짐에 따라 수요가 촉진되고 있습니다. 혁신적인 약물 요법의 도입과 관련된 연구개발 활동의 강화는 다양한 증상 프로파일을 가진 환자에게 더 맞춤형 솔루션을 제공함으로써 시장 성장에 기여합니다.

시장 성장 억제요인 :

유망한 성장이 예상되는 것, 섬유근육통 치료 시장은 고급 치료 비용과 병리학의 정확한 진단 복잡성과 관련된 문제에 직면해 있습니다. 지역에 따라서는 전문적인 치료에의 액세스가 한정되어 있는 것, 비침습적이기 때문에 일부 환자에게 선호되는 홀리스틱 의료나 보완 의료 등의 대체 치료를 이용할 수 있는 것이, 시장의 성장을 방해할 수 있습니다. 게다가, 이 질환의 만성적인 성질과 치료법의 부족은 장기적인 관리에 지속적인 도전을 가져옵니다. 이러한 문제를 해결하기 위해 섬유근육통의 근본 원인을 더 잘 이해하고 치료의 효능, 합리적인 가격 및 사용 편의성을 개선하기 위해 조사에 지속적인 투자가 필요합니다.

시장 기회 :

이 시장은 환자의 결과를 개선하는 집학적 치료 접근법의 채용 증가로 큰 비즈니스 기회를 제공합니다. 새로운 유형의 항우울제, 항경련제, 근육 이완제 등의 신약 요법의 개발은 보다 효과적인 증상 관리에 대한 요구 증가에 대응하고 있습니다. 신흥 시장의 의료 인프라 확장은 시장 성장을 위한 새로운 채널을 제공하며, 기업은 더 많은 환자 집단에 도달하고 최첨단 치료에 대한 액세스를 제공할 수 있습니다. 전략적 파트너십, 환자 교육 프로그램 투자, 원격 관리를 위한 원격 의료 플랫폼의 도입은 새로운 기회를 활용하고 시장에서 리더십을 유지하는 데 필수적입니다.

이 보고서에서 다루는 주요 질문

세계의 섬유근육통 치료 시장 성장을 가속하는 주요 요인은 무엇인가?
다양한 건강 관리 환경에서 어떤 유형의 치료가 채용을 이끌고 있는가?
기술의 진보는 섬유근육통 치료 시장 경쟁 구도에 어떤 영향을 미치는가?
섬유근육통 치료 시장의 주요 기업은 누구이며 경쟁력을 유지하기 위해 어떤 전략을 채택하고 있는가?
세계의 섬유근육통 치료 시장에서 새로운 동향 및 전망은?

서문 : 주요 조사 결과
시장 규모(10억 달러) 분석(2019-2023년)
시장 규모(10억 달러) 분석 및 예측(2024-2033년)
- 항우울제
  - 벤라팍신
  - 듀록세틴 염산염
  - 밀나시플란 염산염
  - 기타
- 항경련제
  - 프레가 발린
  - 가바펜틴
  - 기타
- 근육 이완제
- 진통제
시장의 매력 분석 : 약제 클래스별

제9장 세계의 섬유근육통 치료 시장 분석 : 유통 채널별

서문 : 주요 조사 결과
시장 규모(10억 달러) 분석(2019-2023년)
시장 규모(10억 달러) 분석 및 예측(2024-2033년)
- 병원 약국
- 약국
- 소매 약국
- 온라인 약국
시장의 매력 분석 : 유통 채널별

제10장 세계의 섬유근육통 치료 시장 분석 : 지역별

서문
시장 규모(10억 달러) 분석(2019-2023년)
시장 규모(10억 달러) 분석 및 예측(2024-2033년)
- 북미
- 라틴아메리카
- 유럽
- 동아시아
- 남아시아
- 오세아니아
- 중동 및 아프리카(중동 및 아프리카)
시장의 매력 분석 : 지역별

제11장 북미의 섬유근육통 치료 시장 분석

제12장 라틴아메리카의 섬유근육통 치료 시장 분석

제13장 유럽의 섬유근육통 치료 시장 분석

제14장 동아시아의 섬유근육통 치료 시장 분석

제15장 남아시아의 섬유근육통 치료 시장 분석

제16장 오세아니아의 섬유근육통 치료 시장

제17장 중동 및 아프리카의 섬유근육통 치료 시장 분석

제18장 시장 구조 분석

기업 Tier별 시장 분석
주요 기업의 시장 점유율 분석
시장 현재 분석

제19장 경쟁 분석

경쟁 대시보드
경쟁의 상세
- FSD Pharma
- Pfizer, Inc.
- Eli Lilly and Company
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
- Johnson &Johnson Services, Inc
- Sanofi
- GlaxoSmithKline plc.
- Bayer AG
- TONIX Pharmaceuticals Holdings Corp
- Virios Therapeutics, Inc.
- Aptinyx Inc.

제20장 사용된 전제조건 및 약어

제21장 조사 방법

AJY

영문 목차

영문목차

Persistence Market Research has recently published an extensive report on the global Fibromyalgia Treatment Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

Fibromyalgia Treatment Market Size (2024E): USD 1.5 Billion
Projected Market Value (2033F): USD 2.7 Billion
Global Market Growth Rate (CAGR 2024 to 2033): 6.7%

Fibromyalgia Treatment Market - Report Scope:

The Fibromyalgia Treatment Market encompasses a wide range of therapeutic approaches used to manage the chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive disturbances. Fibromyalgia affects millions worldwide, and its management often involves medications, physical therapy, and lifestyle changes. The market serves multiple segments, including hospitals, specialty clinics, and rehabilitation centers. Growth is driven by the increasing awareness of fibromyalgia, advancements in therapeutic treatments, and the expanding use of multidisciplinary approaches for symptom management across various healthcare settings.

Market Growth Drivers:

Several key factors are driving the global Fibromyalgia Treatment Market. The rising incidence of fibromyalgia globally is boosting the market's growth as more patients seek effective treatments for this condition. Technological advancements in treatment options, such as new pharmaceutical formulations, non-drug therapies, and telehealth applications, have improved the efficacy and accessibility of fibromyalgia management, further fueling market expansion. Additionally, growing awareness of the importance of early diagnosis and the development of personalized treatment plans is driving demand. Enhanced research and development activities, along with the introduction of innovative drug therapies, contribute to market growth by offering more tailored solutions for patients with varying symptom profiles.

Market Restraints:

Despite promising growth prospects, the Fibromyalgia Treatment Market faces challenges related to the high costs of advanced therapies and the complexities of accurately diagnosing the condition. Market growth can be hindered by limited access to specialized care in certain regions and the availability of alternative treatments such as holistic or complementary medicine, which may be preferred by some patients due to their non-invasive nature. Additionally, the chronic nature of the condition and the lack of a cure present ongoing challenges for long-term management. Addressing these issues requires continued investment in research to better understand the underlying causes of fibromyalgia and to improve treatment efficacy, affordability, and accessibility.

Market Opportunities:

The market presents significant opportunities driven by the increasing adoption of multidisciplinary treatment approaches, which offer improved patient outcomes. The development of new drug therapies, including novel classes of antidepressants, anticonvulsants, and muscle relaxants, caters to the growing need for more effective symptom management. The expansion of healthcare infrastructure in emerging markets provides new channels for market growth, allowing companies to reach a broader patient population and offer access to cutting-edge treatments. Strategic partnerships, investments in patient education programs, and the introduction of telemedicine platforms for remote management are essential for capitalizing on emerging opportunities and maintaining market leadership.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the Fibromyalgia Treatment Market globally?
Which types of treatments are leading the adoption in various healthcare settings?
How are technological advancements influencing the competitive landscape of the Fibromyalgia Treatment Market?
Who are the key players in the Fibromyalgia Treatment Market, and what strategies are they employing to stay competitive?
What are the emerging trends and future prospects in the global Fibromyalgia Treatment Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Fibromyalgia Treatment Market, including Pfizer, Inc., Eli Lilly and Company, and Teva Pharmaceuticals, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced drug formulations and explore non-drug therapies. Collaborations with healthcare providers, research institutions, and technology developers facilitate market access and promote new treatment adoption. Emphasis on patient education, high-quality treatments, and comprehensive support programs fosters market growth and enhances brand loyalty in the evolving Fibromyalgia Treatment Market landscape.

Key Companies Profiled:

FSD Pharma
Pfizer, Inc.
Eli Lilly and Company
AbbVie, Inc.
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc
Sanofi
GlaxoSmithKline plc.
Bayer AG
TONIX Pharmaceuticals Holdings Corp
Virios Therapeutics, Inc.
Aptinyx Inc.

Fibromyalgia Treatment Market Industry Segmentation:

Drug Class:

Antidepressants
Anticonvulsants
Muscle Relaxants
Analgesics

Distribution Channel:

Hospitals Pharmacies
Drug Stores
Retail Pharmacies
Online Pharmacies

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Drug Class Innovation / Development Trends

4. Key Success Factors

4.1. Drug Class Adoption Analysis
4.2. Key Regulations
4.3. Recent Drug Class launches/ Approvals
4.4. PESTEL Analysis
4.5. Pipeline Assessment
4.6. Key Promotional Strategies, By Key Players
4.7. Porter's Analysis
4.8. Value Chain Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Global Musculoskeletal Disorder drugs market
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Increase in R&D Spending
- 5.2.2. Growing Disease Prevalence
- 5.2.3. Cost of Drug Class
- 5.2.4. Drug Class Features
- 5.2.5. New Drug Class approvals
- 5.2.6. Drug Class Pipeline
- 5.2.7. Changes in Regulatory Policies
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Drug Class
- 6.1.2. By Distribution Channel
- 6.1.3. By Country
6.2. 2022 Market Scenario

7. Global Fibromyalgia Treatment Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Class

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Drug Class, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Class, 2024-2033
- 8.3.1. Antidepressants
  - 8.3.1.1. Venlafaxine
  - 8.3.1.2. Duloxetine HCl
  - 8.3.1.3. Milnacipran HCl
  - 8.3.1.4. Others
- 8.3.2. Anticonvulsants
  - 8.3.2.1. Pregabalin
  - 8.3.2.2. Gabapentin
  - 8.3.2.3. Others
- 8.3.3. Muscle Relaxants
- 8.3.4. Analgesics
8.4. Market Attractiveness Analysis By Drug Class

9. Global Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
- 9.3.1. Hospitals Pharmacies
- 9.3.2. Drug Stores
- 9.3.3. Retail Pharmacies
- 9.3.4. Online Pharmacies
9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Region

10.1. Introduction
10.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
10.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
- 10.3.1. North America
- 10.3.2. Latin America
- 10.3.3. Europe
- 10.3.4. East Asia
- 10.3.5. South Asia
- 10.3.6. Oceania
- 10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region

11. North America Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

11.1. Introduction
11.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 11.3.1. By Country
  - 11.3.1.1. U.S.
  - 11.3.1.2. Canada
- 11.3.2. By Drug Class
- 11.3.3. By Distribution Channel
11.4. Market Attractiveness Analysis
- 11.4.1. By Country
- 11.4.2. By Drug Class
- 11.4.3. By Distribution Channel
11.5. Market Trends
11.6. Drivers and Restraints - Impact Analysis
11.7. Key Players - Intensity Mapping
11.8. Country Level Analysis & Forecast
- 11.8.1. U.S. Fibromyalgia Treatment Market Analysis
  - 11.8.1.1. Introduction
  - 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 11.8.1.2.1. By Drug Class
    - 11.8.1.2.2. By Distribution Channel
- 11.8.2. Canada Fibromyalgia Treatment Market Analysis
  - 11.8.2.1. Introduction
  - 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 11.8.2.2.1. By Drug Class
    - 11.8.2.2.2. By Distribution Channel

12. Latin America Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

12.1. Introduction
12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 12.3.1. By Country
  - 12.3.1.1. Mexico
  - 12.3.1.2. Brazil
  - 12.3.1.3. Argentina
  - 12.3.1.4. Rest of Latin America
- 12.3.2. By Drug Class
- 12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Drug Class
- 12.4.3. By Distribution Channel
12.5. Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Key Players - Intensity Mapping
12.8. Country Level Analysis & Forecast
- 12.8.1. Mexico Fibromyalgia Treatment Market Analysis
  - 12.8.1.1. Introduction
  - 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.1.2.1. By Drug Class
    - 12.8.1.2.2. By Distribution Channel
- 12.8.2. Brazil Fibromyalgia Treatment Market Analysis
  - 12.8.2.1. Introduction
  - 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.2.2.1. By Drug Class
    - 12.8.2.2.2. By Distribution Channel
- 12.8.3. Argentina Fibromyalgia Treatment Market Analysis
  - 12.8.3.1. Introduction
  - 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.3.2.1. By Drug Class
    - 12.8.3.2.2. By Distribution Channel

13. Europe Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 13.3.1. By Country
  - 13.3.1.1. Germany
  - 13.3.1.2. Italy
  - 13.3.1.3. France
  - 13.3.1.4. U.K.
  - 13.3.1.5. Spain
  - 13.3.1.6. BENELUX
  - 13.3.1.7. Russia
  - 13.3.1.8. Rest of Europe
- 13.3.2. By Drug Class
- 13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Drug Class
- 13.4.3. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Key Players - Intensity Mapping
13.8. Country Level Analysis & Forecast
- 13.8.1. Germany Fibromyalgia Treatment Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Drug Class
    - 13.8.1.2.2. By Distribution Channel
- 13.8.2. Italy Fibromyalgia Treatment Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Drug Class
    - 13.8.2.2.2. By Distribution Channel
- 13.8.3. France Fibromyalgia Treatment Market Analysis
  - 13.8.3.1. Introduction
  - 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.3.2.1. By Drug Class
    - 13.8.3.2.2. By Distribution Channel
- 13.8.4. U.K. Fibromyalgia Treatment Market Analysis
  - 13.8.4.1. Introduction
  - 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.4.2.1. By Drug Class
    - 13.8.4.2.2. By Distribution Channel
- 13.8.5. Spain Fibromyalgia Treatment Market Analysis
  - 13.8.5.1. Introduction
  - 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.5.2.1. By Drug Class
    - 13.8.5.2.2. By Distribution Channel
- 13.8.6. BENELUX Fibromyalgia Treatment Market Analysis
  - 13.8.6.1. Introduction
  - 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.6.2.1. By Drug Class
    - 13.8.6.2.2. By Distribution Channel
- 13.8.7. Russia Fibromyalgia Treatment Market Analysis
  - 13.8.7.1. Introduction
  - 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.7.2.1. By Drug Class
    - 13.8.7.2.2. By Distribution Channel

14. East Asia Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

14.1. Introduction
14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 14.3.1. By Country
  - 14.3.1.1. China
  - 14.3.1.2. Japan
  - 14.3.1.3. South Korea
- 14.3.2. By Drug Class
- 14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Drug Class
- 14.4.3. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Players - Intensity Mapping
14.8. Country Level Analysis & Forecast
- 14.8.1. China Fibromyalgia Treatment Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Drug Class
    - 14.8.1.2.2. By Distribution Channel
- 14.8.2. Japan Fibromyalgia Treatment Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Drug Class
    - 14.8.2.2.2. By Distribution Channel
- 14.8.3. South Korea Fibromyalgia Treatment Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Drug Class
    - 14.8.3.2.2. By Distribution Channel

15. South Asia Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 15.3.1. By Country
  - 15.3.1.1. India
  - 15.3.1.2. Indonesia
  - 15.3.1.3. Malaysia
  - 15.3.1.4. Thailand
  - 15.3.1.5. Rest of South Asia
- 15.3.2. By Drug Class
- 15.3.3. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug Class
- 15.4.3. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Players - Intensity Mapping
15.8. Country Level Analysis & Forecast
- 15.8.1. India Fibromyalgia Treatment Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Drug Class
    - 15.8.1.2.2. By Distribution Channel
- 15.8.2. Indonesia Fibromyalgia Treatment Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Drug Class
    - 15.8.2.2.2. By Distribution Channel
- 15.8.3. Malaysia Fibromyalgia Treatment Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Drug Class
    - 15.8.3.2.2. By Distribution Channel
- 15.8.4. Thailand Fibromyalgia Treatment Market Analysis
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.4.2.1. By Drug Class
    - 15.8.4.2.2. By Distribution Channel

16. Oceania Fibromyalgia Treatment Market 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 16.3.1. By Country
  - 16.3.1.1. Australia
  - 16.3.1.2. New Zealand
- 16.3.2. By Drug Class
- 16.3.3. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Drug Class
- 16.4.3. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Players - Intensity Mapping
16.8. Country Level Analysis & Forecast
- 16.8.1. Australia Fibromyalgia Treatment Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Drug Class
    - 16.8.1.2.2. By Distribution Channel
- 16.8.2. New Zealand Fibromyalgia Treatment Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Drug Class
    - 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Fibromyalgia Treatment Market Analysis 2019-2023 and Forecast 2024-2033

17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 17.3.1. By Country
  - 17.3.1.1. GCC Countries
  - 17.3.1.2. Turkey
  - 17.3.1.3. North Africa
  - 17.3.1.4. South Africa
  - 17.3.1.5. Rest of Middle East and Africa
- 17.3.2. By Drug Class
- 17.3.3. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug Class
- 17.4.3. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Players - Intensity Mapping
17.8. Country Level Analysis & Forecast
- 17.8.1. GCC Countries Fibromyalgia Treatment Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Drug Class
    - 17.8.1.2.2. By Distribution Channel
- 17.8.2. Turkey Fibromyalgia Treatment Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Drug Class
    - 17.8.2.2.2. By Distribution Channel
- 17.8.3. South Africa Fibromyalgia Treatment Market Analysis
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.3.2.1. By Drug Class
    - 17.8.3.2.2. By Distribution Channel
- 17.8.4. North Africa Fibromyalgia Treatment Market Analysis
  - 17.8.4.1. Introduction
  - 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.4.2.1. By Drug Class
    - 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis

19. Competition Analysis

19.1. Competition Dashboard
19.2. Competition Deep Dive
- 19.2.1. FSD Pharma
  - 19.2.1.1. Overview
  - 19.2.1.2. Product Portfolio
  - 19.2.1.3. Sales Footprint
  - 19.2.1.4. Key Financials
  - 19.2.1.5. SWOT Analysis
  - 19.2.1.6. Strategy Overview
    - 19.2.1.6.1. Marketing Strategy
    - 19.2.1.6.2. Product Strategy
    - 19.2.1.6.3. Channel Strategy
- 19.2.2. Pfizer, Inc.
  - 19.2.2.1. Overview
  - 19.2.2.2. Product Portfolio
  - 19.2.2.3. Sales Footprint
  - 19.2.2.4. Key Financials
  - 19.2.2.5. SWOT Analysis
  - 19.2.2.6. Strategy Overview
    - 19.2.2.6.1. Marketing Strategy
    - 19.2.2.6.2. Product Strategy
    - 19.2.2.6.3. Channel Strategy
- 19.2.3. Eli Lilly and Company
  - 19.2.3.1. Overview
  - 19.2.3.2. Product Portfolio
  - 19.2.3.3. Sales Footprint
  - 19.2.3.4. Key Financials
  - 19.2.3.5. SWOT Analysis
  - 19.2.3.6. Strategy Overview
    - 19.2.3.6.1. Marketing Strategy
    - 19.2.3.6.2. Product Strategy
    - 19.2.3.6.3. Channel Strategy
- 19.2.4. AbbVie, Inc.
  - 19.2.4.1. Overview
  - 19.2.4.2. Product Portfolio
  - 19.2.4.3. Sales Footprint
  - 19.2.4.4. Key Financials
  - 19.2.4.5. SWOT Analysis
  - 19.2.4.6. Strategy Overview
    - 19.2.4.6.1. Marketing Strategy
    - 19.2.4.6.2. Product Strategy
    - 19.2.4.6.3. Channel Strategy
- 19.2.5. Teva Pharmaceutical Industries Ltd.
  - 19.2.5.1. Overview
  - 19.2.5.2. Product Portfolio
  - 19.2.5.3. Sales Footprint
  - 19.2.5.4. Key Financials
  - 19.2.5.5. SWOT Analysis
  - 19.2.5.6. Strategy Overview
    - 19.2.5.6.1. Marketing Strategy
    - 19.2.5.6.2. Product Strategy
    - 19.2.5.6.3. Channel Strategy
- 19.2.6. Johnson & Johnson Services, Inc
  - 19.2.6.1. Overview
  - 19.2.6.2. Product Portfolio
  - 19.2.6.3. Sales Footprint
  - 19.2.6.4. Key Financials
  - 19.2.6.5. SWOT Analysis
  - 19.2.6.6. Strategy Overview
    - 19.2.6.6.1. Marketing Strategy
    - 19.2.6.6.2. Product Strategy
    - 19.2.6.6.3. Channel Strategy
- 19.2.7. Sanofi
  - 19.2.7.1. Overview
  - 19.2.7.2. Product Portfolio
  - 19.2.7.3. Sales Footprint
  - 19.2.7.4. Key Financials
  - 19.2.7.5. SWOT Analysis
  - 19.2.7.6. Strategy Overview
    - 19.2.7.6.1. Marketing Strategy
    - 19.2.7.6.2. Product Strategy
    - 19.2.7.6.3. Channel Strategy
- 19.2.8. GlaxoSmithKline plc.
  - 19.2.8.1. Overview
  - 19.2.8.2. Product Portfolio
  - 19.2.8.3. Sales Footprint
  - 19.2.8.4. Key Financials
  - 19.2.8.5. SWOT Analysis
  - 19.2.8.6. Strategy Overview
    - 19.2.8.6.1. Marketing Strategy
    - 19.2.8.6.2. Product Strategy
    - 19.2.8.6.3. Channel Strategy
- 19.2.9. Bayer AG
  - 19.2.9.1. Overview
  - 19.2.9.2. Product Portfolio
  - 19.2.9.3. Sales Footprint
  - 19.2.9.4. Key Financials
  - 19.2.9.5. SWOT Analysis
  - 19.2.9.6. Strategy Overview
    - 19.2.9.6.1. Marketing Strategy
    - 19.2.9.6.2. Product Strategy
    - 19.2.9.6.3. Channel Strategy
- 19.2.10. TONIX Pharmaceuticals Holdings Corp
  - 19.2.10.1. Overview
  - 19.2.10.2. Product Portfolio
  - 19.2.10.3. Sales Footprint
  - 19.2.10.4. Key Financials
  - 19.2.10.5. SWOT Analysis
  - 19.2.10.6. Strategy Overview
    - 19.2.10.6.1. Marketing Strategy
    - 19.2.10.6.2. Product Strategy
    - 19.2.10.6.3. Channel Strategy
- 19.2.11. Virios Therapeutics, Inc.
  - 19.2.11.1. Overview
  - 19.2.11.2. Product Portfolio
  - 19.2.11.3. Sales Footprint
  - 19.2.11.4. Key Financials
  - 19.2.11.5. SWOT Analysis
  - 19.2.11.6. Strategy Overview
    - 19.2.11.6.1. Marketing Strategy
    - 19.2.11.6.2. Product Strategy
    - 19.2.11.6.3. Channel Strategy
- 19.2.12. Aptinyx Inc.
  - 19.2.12.1. Overview
  - 19.2.12.2. Product Portfolio
  - 19.2.12.3. Sales Footprint
  - 19.2.12.4. Key Financials
  - 19.2.12.5. SWOT Analysis
  - 19.2.12.6. Strategy Overview
    - 19.2.12.6.1. Marketing Strategy
    - 19.2.12.6.2. Product Strategy
    - 19.2.12.6.3. Channel Strategy